Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- 03 Jun 2010 New trial record